SILO Financials: Silo Pharma Inc AI Analysis



Financials

SILO Financial

Silo Pharma Inc

$0.45

-2.16%

$-0.01

At close: May 05, 16:00:00 GMT-4

$0.44

-2.43%

$-0.01

Pre-market: May 06, 07:36:04 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$0.461

Open

$0.4696

Day's Range

$0.44 - $0.4696

52 week range

$0.221 - $1.15

Volume

171.8K

Avg.Volume

3.4M

Dividend yield

EPS (TTM)

-0.61

Market Cap

$6.2M

What is SILO?

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Features

Markets

News

Income

Balance sheet

Cash flow

Annual

Quarterly

SILO Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
Selling, General & Admin	2	0	0	0	0	0
Research & Development	2	0	0	0	0	1
Operating Expenses	4	0	1	1	1	1
Other Non Operating Income (Expenses)	0	0	0	--	--	--
Pretax Income	-4	0	-1	-1	-1	-1
Income Tax Expense	--	--	0	0	0	--
Net Income	-4	0	-1	-1	-1	-1
Net Income Growth	0%	-100%	--	--	--	0%
Shares Outstanding (Diluted)	13.37	13.37	9.33	6.27	4.48	4.49
Shares Change (YoY)	198%	198%	117%	106%	56%	55%
EPS (Diluted)	-0.31	-0.06	-0.11	-0.19	-0.23	-0.38
EPS Growth	-68%	-83%	-45%	-37%	-18%	1%
Free Cash Flow	-5	-1	-1	-1	-1	0
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	0%	0%	0%	0%	0%	0%
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-4	0	-1	-1	-1	-1
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-4	0	-1	-1	-1	-1
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	--	--	0%	0%	0%	--

Follow-Up Questions

What are Silo Pharma Inc's key financial statements?



According to the latest financial statement (Form-10K), Silo Pharma Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for SILO?



Silo Pharma Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Silo Pharma Inc's revenue broken down by segment or geography?



Silo Pharma Inc largest revenue segment is Biopharmaceutical, at a revenue of 72,102 in the most earnings release.For geography, United States is the primary market for Silo Pharma Inc, at a revenue of 72,102.

Is Silo Pharma Inc profitable?



no, according to the latest financial statements, Silo Pharma Inc has a net loss of $0

Does Silo Pharma Inc have any liabilities?



no, Silo Pharma Inc has liability of 0

How many outstanding shares for Silo Pharma Inc?



Silo Pharma Inc has a total outstanding shares of 0

Silo Pharma Inc (SILO) Financial

SILO Stock Price Chart